IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Despite the bleak political situation (from the standpoint of Polish patriots), economic progress was made in the lands taken over by foreign powers because the period after the Congress of Vienna witnessed a significant development in the building of early industry. Economic historians have made new estimates on GDP per capita, 1790–1910. They confirm the hypothesis of semi-peripheral development of Polish territories in the 19th century and the slow process of catching-up with the core economies.
The balance of power theory in international relations suggests that states may secure their survival by preventing any one state from gaining enough military power to dominate all others. If one state becomes much stronger, the theory predicts it will take advantage of its weaker neighbors, thereby driving them to unite in a defensive coalition. Some realists maintain that a balance-of-power system is more stable than one with a dominant state, as aggression is unprofitable when there is equilibrium of power between rival coalitions. When threatened, states may seek safety either by balancing, allying with others against the prevailing threat; or bandwagoning, aligning themselves with the threatening power. Other alliance tactics include buck passing and chain-ganging. Realists have long debated how the polarity of a system impacts the choice of tactics; however, it is generally agreed that in bipolar systems, each great power has no choice but to directly confront the other. Along with debates between realists about the prevalence of balancing in alliance patterns, other schools of international relations, such as constructivists, are also critical of the balance of power theory, disputing core realist assumptions regarding the international system and the behavior of states.
2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.
The Tandem Diabetes Care t:Slim X2 was approved by the U.S. Food and Drug Administration in 2019 and is the first insulin pump to be designated as an alternate controller enabled (ACE) insulin pump. ACE insulin pumps allow users to integrate continuous glucose monitors, automated insulin dosing (AID) systems, and other diabetes management devices with the pump to create a personalized diabetes therapy system. Many users of the t:slim X2 integrate the pump with the Dexcom G6, a continuous glucose monitor approved by the FDA in 2018. It was the first CGM authorized for use in an integrated therapy system. The device does not require fingerstick calibrations.
To determine saponification value, the sample is treated with an excess of alkali (usually an ethanolic solution of potassium hydroxide) for half an hour under reflux. The KOH is consumed by reaction with triglycerides, which consume three equivalents of base. Diglycerides consume two equivalents of KOH. Monoglycerides and free fatty acids, as well as other esters such as lactones, consume one equivalent of base. At the end of the reaction the quantity of KOH is determined by titration using standard solution of hydrochloric acid (HCl). Key to the method is the use of phenolphthalein indicator, which indicates the consumption of strong base (KOH) by the acid, not the weak base (potassium carboxylates). The SV (mg KOH/ g of sample) is calculated as following: Eq. 1 where: B {\displaystyle {\textrm {B}}} is the volume of HCl solution used for the blank run, in mL; S {\displaystyle {\textrm {S}}} is the volume of HCl solution used for the tested sample, in mL; M {\displaystyle {\textrm {M}}} is the molarity of HCl solution, in mol / L; 56.1 is the molecular weight of KOH, in g / mol; W
Sources: en.wikipedia.org
12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis. Since it mediates 12(S)-HETE-induced itching in the mouse model, BLT2 rather than GPR31 may mediate human itch in these reactions.
The PTB2 RNA motif is a conserved intronic RNA element identified in plant homologs of the polypyrimidine tract-binding protein 2 (PTB2) gene that has been reported as a cis-regulatory element. PTB2 is an RNA motif reported as a stem-loop structure, with the loop containing a conserved GUGUGU sequence that encompasses the 5′ splice site of a cassette exon involved in alternative splicing. The 3' side of the stem contains a long conserved pyrimidine-rich tract. The PTB2 RNA motif was identified in homologous of 93 species of Pentapetalae plants. The long conserved pyrimidine-rich tract located on the 3′ side of the PTB2 RNA motif stem suggests a role in regulation of PTB2 genes. The co-occurrence of the PTB2 RNA motif and PTB2 genes is consistent with a mechanistic link between RNA secondary structure and PTB-mediated splicing regulation. The motif has been proposed to contribute to regulation of PTB2 expression by influencing PTB1/PTB2 binding and promoting cassette exon inclusion during alternative splicing, which can lead to nonsense-mediated decay of the resulting transcript.
33. Eksp Klin Farmakol. 2006 Nov-Dec;69(6):13-6. [Comparative study of the effects of melatonin and epitalon on the protracted memory under the shuttle labyrinth test conditions in rats in the course of aging]. [Article in Russian] Vinogradova IA. The influence of the chronic administration of melatonin (epiphyseal hormone) and epitalon (a synthetic tetrapeptide increasing melatonin production) on the learning process and the protracted memory has been studied in LIO rats in the course of aging for 2 years under standard illumination regime (12L :12D). The daily administration of melatonin (Sigma, USA) with drinking water (in 10 mg/liter dose at night) in rats beginning with the age of 4 months did not influence the learning processes in young and adult animals but it was found to contribute to optimization of the brain cognitive function in rats in the course of aging, by improving the protracted memory process. Epitalon administered in a daily dose of 0.1 microg per animal beginning with the age of 4 months showed mnemotropic properties (decreasing the extent of memory disorders) in old rats under conditions of the shuttle labyrinth test.
== Animal harvesting == When not synthesized, collagen can be harvested from animal skin. This has led to deforestation, as has occurred in Paraguay, where large collagen producers buy large numbers of cattle hides from regions that have been clear-cut for cattle grazing.
Sources: en.wikipedia.org
=== Hepatotoxicity === Moderate to severe acute hepatitis has occurred in several adults who had been taking the drug at the recommended dose for two to four weeks. Plasma rosiglitazone concentrations may be increased in people with existing liver problems.
On July 13, 2024, Trump survived an assassination attempt while addressing a campaign rally near Butler, Pennsylvania. Trump was shot at by Thomas Crooks, a 20-year-old man from Bethel Park, Pennsylvania, who fired eight rounds with an AR-15–style rifle from the roof of a building located approximately 400 feet (120 meters) from the stage. According to the FBI, Trump was hit by a bullet, and injured in his upper right ear. He raised a hand to his ear before dropping down on his podium behind the lectern for cover. Secret Service agents lunged toward Trump and shielded him. After the assailant was declared "down", agents helped Trump get up. Blood was visible on his ear and face. He asked the Secret Service agents to let him get his shoes. According to Trump, the agents "hit me so hard that my shoes fell off, and my shoes are tight." As of October 12, 2024, none of the medical records pertaining to his wounds had been released. In July 2024, psychologist Simon McCarthy-Jones of Trinity College Dublin said in The Conversation that "the potential effect of the attempted assassination of Trump upon Trump's mental health – whether negligible, negative or positive – cannot be ignored". McCarthy-Jones stated that Trump being an extrovert might improve his ability to deal with the psychological impact of the event.
Although early medical experimentation was performed often, the use of a control group to provide an accurate comparison for the demonstration of the intervention's efficacy was generally lacking. For instance, Lady Mary Wortley Montagu, who campaigned for the introduction of inoculation (then called variolation) to prevent smallpox, arranged for seven prisoners who had been sentenced to death to undergo variolation in exchange for their life. Although they survived and did not contract smallpox, there was no control group to assess whether this result was due to the inoculation or some other factor. Similar experiments performed by Edward Jenner over his smallpox vaccine were equally conceptually flawed. The first proper clinical trial was conducted by the Scottish physician James Lind. The disease scurvy, now known to be caused by a Vitamin C deficiency, would often have terrible effects on the welfare of the crew of long-distance ocean voyages. In 1740, the catastrophic result of Anson's circumnavigation attracted much attention in Europe; out of 1900 men, 1400 had died, most of them allegedly from having contracted scurvy. John Woodall, an English military surgeon of the British East India Company, had recommended the consumption of citrus fruit from the 17th century, but their use did not become widespread. Lind conducted the first systematic clinical trial in 1747. He included a dietary supplement of an acidic quality in the experiment after two months at sea, when the ship was already afflicted with scurvy. He divided twelve scorbutic sailors into six groups of two.
=== Functions of inhibitors === In many organisms, inhibitors may act as part of a feedback mechanism. If an enzyme produces too much of one substance in the organism, that substance may act as an inhibitor for the enzyme at the beginning of the pathway that produces it, causing production of the substance to slow down or stop when there is sufficient amount. This is a form of negative feedback. Major metabolic pathways such as the citric acid cycle make use of this mechanism. Since inhibitors modulate the function of enzymes they are often used as drugs. Many such drugs are reversible competitive inhibitors that resemble the enzyme's native substrate, similar to methotrexate above; other well-known examples include statins used to treat high cholesterol, and protease inhibitors used to treat retroviral infections such as HIV. A common example of an irreversible inhibitor that is used as a drug is aspirin, which inhibits the COX-1 and COX-2 enzymes that produce the inflammation messenger prostaglandin. Other enzyme inhibitors are poisons. For example, the poison cyanide is an irreversible enzyme inhibitor that combines with the copper and iron in the active site of the enzyme cytochrome c oxidase and blocks cellular respiration.
Retrolental tract: Extends posteriorly from the hyaloideocapsular ligament into central vitreous Coronary tract: External to the retrolental tract, and excluding posteriorly from a circular zone overlying the posterior 1/3rd of the ciliary processes Median tract: Extends back from a circular zone external to the coronary tract, at the anterior margin of the vitreous base Preretinal tract: Extends back from the ora serrata and vitreous base
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.